The purpose of this study is to determine whether 2 weeks of treatment with AZD1446 compared to placebo improves ADHD symptoms and is well tolerated.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
135
Research Site
Los Alamitos, California, United States
Research Site
Fort Myers, Florida, United States
Research Site
New York, New York, United States
Research Site
Austin, Texas, United States
AZD1446 compared to placebo, improves ADHD core symptoms in adult non-users and users of nicotine products after 2 weeks of treatment as measured by the Conners' Adult ADHD Rating Scale-Investigator Rated (CAARS-INV) Total ADHD Symptoms score (18 item)
Time frame: The CAARS-INV will be administered once at each of the following visits: Visit 1; Visit 2; Visits 3,4,5; Visit 7; Visits 8, 9, 10; Visit 12; and Visits 13, 14 and 15
To evaluate the effect of AZD1446 treatment compared to placebo on ADHD symptoms as derived from the 30 item Conners' Adult ADHD Rating Scale-Investigator Rated (CAARS-INV) scoring
Time frame: Visit 1; Visit 2; Visits 3,4,5; Visit 7; Visits 8, 9, 10; Visit 12; and Visits 13, 14 and 15
To assess the safety and tolerability of effects of 2 weeks treatment with AZD1446 compared to placebo.
Time frame: From enrollment visit to follow up
To evaluate the pharmacokinetics (PK) of AZD1446.
Time frame: Visits 2,3, 4 7, 8, 9 12, 13 and 14 PK will be collected
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Matching capsule, oral dose
Research Site
Burlington, Vermont, United States
Research Site
Seattle, Washington, United States